NCT04161066View on ClinicalTrials.gov

Adjunctive Effects of Psilocybin and a Formulation of Buprenorphine

PHASE1RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

January 13, 2021

Primary Completion Date

June 30, 2026

Study Completion Date

July 31, 2026

Conditions
Opioid Use Disorder
Interventions
DRUG

Psilocybin with facilitated counseling

open-label pilot study

Trial Locations (1)

53705

RECRUITING

University of Wisconsin, Madison

Sponsors
All Listed Sponsors
collaborator

Heffter Research Institute

OTHER

collaborator

Etheridge Foundation

UNKNOWN

lead

University of Wisconsin, Madison

OTHER